Nano-X Imaging Ltd. Stock Price, News & Analysis

NANO-X IMAGING LTD (NASDAQ: NNOX) will announce its Q2 2021 financial results on August 10, 2021, prior to market open. A conference call and webcast will be held at 8:30 AM ET on the same day. The company aims to revolutionize medical imaging with its commercial-grade digital X-ray technology, designed to lower costs and improve accessibility. Nanox plans to partner with leading healthcare organizations to enhance early detection services. Further details can be found on their website.

NANO-X IMAGING LTD (NNOX) has entered the West African market by signing an exclusive distribution agreement with EiLEENO Pharma to deploy 1,000 Nanox Systems in Nigeria, pending regulatory approval. This collaboration aims to enhance medical imaging availability and improve healthcare standards in the country. The agreement has a four-year term with annual service fees from EiLEENO Pharma. The Nanox System includes the innovative Nanox.ARC imaging device and Nanox.CLOUD software, which promises to facilitate accessible healthcare services across roughly 4,400 health facilities in Nigeria.

NANO-X IMAGING LTD (NASDAQ: NNOX) announced that CEO Ran Poliakine will present at the Ladenburg Thalmann Healthcare Conference on July 14, 2021, at 10:00 AM ET. The live presentation can be accessed through a webcast, and a replay will be available after the event. Nanox focuses on developing a digital X-ray source aimed at reducing medical imaging costs and providing affordable early detection services. Interested parties can find more details on the company's investor relations website.

NANOX IMAGING LTD (NASDAQ: NNOX) announced a significant milestone by submitting a 510(k) premarket notification to the FDA for its multi-source Nanox.ARC 3-D digital tomosynthesis system. This system aims to address the global need for accessible and cost-effective medical imaging. The submission is a crucial step in the U.S. regulatory process following the FDA clearance of its single source Nanox Cart X-Ray System in April 2021. NANOX plans to develop future versions of the Nanox.ARC to fulfill existing service contracts and collaborations.

NANO-X IMAGING LTD (NASDAQ: NNOX) announces that Chairman and CEO Ran Poliakine will present at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. Poliakine's presentation is set for June 4 at 10:00 AM ET and will be available via a live webcast on the company's website. Nanox aims to develop a commercial-grade digital X-ray technology to reduce medical imaging costs and improve early detection services. The webcast replay will be available post-presentation. For further information, visit www.nanox.vision.

NANO-X IMAGING LTD (NASDAQ: NNOX) announced that CEO Ran Poliakine will present at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. His presentation is set for June 3 at 4:30 PM ET, accessible via a live webcast at wsw.com. The company aims to revolutionize medical imaging with its innovative digital X-ray technology, potentially reducing costs and improving early detection services globally. More information can be found on their website, nanox.vision.

NANO-X IMAGING LTD (NASDAQ: NNOX) announced that CEO Ran Poliakine will present at the Berenberg Virtual Conference from May 18-20, 2021. Poliakine's presentation is set for May 19 at 9:00am ET and will be available via a live webcast. Interested stakeholders can access the audio from the Investor Relations section of Nanox's website, where a replay will also be available. Nanox is developing a digital X-ray source aimed at reducing medical imaging costs and is looking to collaborate with leading healthcare organizations.

Nano-X Imaging announced FDA 510(k) clearance for its Nanox Cart X-Ray System on April 2, 2021, marking a significant milestone. The company aims to submit approval for its multi-source device later this year. Despite progress, shipment of 1,000 multi-source units originally scheduled for Q1 2022 will be delayed. The company ended Q1 2021 with $219 million in cash, up from $7.4 million net loss in Q1 2020. Increases in R&D and administrative expenses were noted, with a total net loss of $12.7 million for the quarter, compared to previous losses.

NANOX IMAGING LTD (NASDAQ: NNOX) appointed Moshe Shtengel as Chief Business Officer on May 2, 2021. With extensive experience in medical business development, Shtengel previously led sales and marketing at Tuttnauer and held key positions at Lumenis and Truphatek. His expertise is expected to enhance Nanox's commercial strategy as they prepare for the launch of their novel Nanox.ARC digital x-ray technology, which has received FDA clearance. The company aims to democratize medical imaging globally.